Point Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Point Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Point Therapeutics: 7 sponsored US clinical trials, none currently recruiting.
Point Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Skin Cancer, with 1 trials.
Upper-quartile sponsor footprint
Point Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00290017
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00243204
Study of Talabostat and Cisplatin in Advanced Melanoma
NCT00083252
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203
Study of Talabostat in Advanced Melanoma
NCT00083239
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
NCT00080080
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
NCT00116389
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 2 |
Therapeutic Areas
How the Point Therapeutics early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Skin Cancer (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Point Therapeutics: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Point Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Point Therapeutics or any single study.
- None of Point Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Skin Cancer is the condition Point Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Skin Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Point Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.